U.S. IPO Market Hit Two-year High as Activity Surges in the Second Quarter
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
Sector Update: Health Care
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
CG Oncology Bladder Cancer Treatment to Achieve $4 Billion in Sales by 2037, BofA Says
CG Oncology's (CGON) cretostimogene immunotherapy to treat bladder cancer is expected to achieve over $4 billion in non-risk adjusted sales by 2037, BofA Securities said in a note Friday. Cretostimoge
A Closer Look at 9 Analyst Recommendations For CG Oncology
9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates their re
Express News | CG Oncology Inc : BofA Global Research Initiates Coverage With Buy Rating; Price Objective $65
CG Oncology Initiated at Buy by B of A Securities
CG Oncology Initiated at Buy by B of A Securities
Express News | B of A Securities Initiates Coverage On CG Oncology With Buy Rating, Announces Price Target of $65
Express News | CG Oncology Initiates Expanded Access Program For Cretostimogene Grenadenorepvec In The US In Non-Muscle Invasive Bladder Cancer Patients Who Are Unresponsive To Bacillus Calmette-Guerin
Express News | CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Foresite Capital Raises $900M to Invest in Healthcare and Life Science Startups at All Stages
SAN FRANCISCO--(BUSINESS WIRE)--#lifesciences--Foresite Capital, a multi-stage healthcare and life sciences investment firm with more than $3.5 billion under management, announced today that it has cl
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Sector Update: Health Care Stocks Softer in Friday Afternoon Trading
Health care stocks were easing Friday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.1%. The iShares Biotechnology ETF (IBB) rose 0
CG Oncology Says Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint
CG Oncology (CGON) said Friday that its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary
Express News | CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology to Present Positive Final Results From Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination With Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
CG Oncology, Inc. (NASDAQ: CGON) today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).
Decoding 10 Analyst Evaluations For CG Oncology
In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent ra